Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells $313,015.56 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 9,724 shares of the firm’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $313,015.56. Following the completion of the transaction, the senior vice president owned 114,678 shares of the company’s stock, valued at approximately $3,691,484.82. This represents a 7.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Paula Green also recently made the following trade(s):

• On Monday, September 22nd, Paula Green sold 295 shares of Twist Bioscience stock. The stock was sold at an average price of $27.56, for a total value of $8,130.20.
• On Monday, September 8th, Paula Green sold 892 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total value of $22,977.92.

Twist Bioscience Stock Down 2.2%

Shares of NASDAQ TWST opened at $31.19 on Friday. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.88 billion, a P/E ratio of -21.51 and a beta of 2.38. The business has a 50-day simple moving average of $27.63 and a two-hundred day simple moving average of $32.66.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TWST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock worth $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. EdgePoint Investment Group Inc. raised its stake in shares of Twist Bioscience by 114.3% during the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company’s stock worth $87,779,000 after acquiring an additional 1,272,732 shares in the last quarter. Nuveen LLC purchased a new position in shares of Twist Bioscience during the first quarter worth approximately $31,960,000. ARK Investment Management LLC raised its stake in shares of Twist Bioscience by 11.5% during the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock worth $245,045,000 after acquiring an additional 645,730 shares in the last quarter. Finally, Balyasny Asset Management L.P. grew its stake in shares of Twist Bioscience by 934.0% during the second quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock valued at $23,113,000 after buying an additional 567,481 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TWST shares. Evercore ISI decreased their target price on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday. Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Barclays cut their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.